ArticleAging2021
The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2017.
Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06062108 (Etude de la prévalence de la Douleur Chez le Patient Cirrhotique hospitalisé), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Etude de la prévalence de la Douleur Chez le Patient Cirrhotique hospitalisé
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Global, regional, and national burden of chronic hepatitis B, 1990-2021, and projections to 2030: An urgent call for action to achieve hepatitis B elimination goals by 2030.Human vaccines & immunotherapeutics · 2026Article
- Changing Etiological Patterns and Predictors of In-Hospital Mortality in Decompensated Cirrhosis: A 10-Year Cohort Study Before and After COVID-19.Diseases (Basel, Switzerland) · 2026Article
- Experimental Study of YaJieShaBa Antialcoholic Hepatic Fibrosis Through TGF-β1/Smad Signaling Pathway.Mediators of inflammation · 2026Article
- Alcohol-related cirrhosis mortality, 1990-2021: temporal trends and development-level inequalities.Gastroenterology and hepatology from bed to bench · 2026Article
- Sina Score as a New Machine Learning-Derived Online Prediction Model of Mortality for Cirrhotic Patients Awaiting Liver Transplantation: A Prospective Cohort Study.Journal of clinical medicine · 2025Article
- The burden of cirrhosis and other chronic liver disease in the middle east and North Africa (MENA) region over three decades.BMC public health · 2024Article
- [Inhibiting Yes-associated protein alleviates CClNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Bone mesenchymal stem cells improve cholestatic liver fibrosis by targeting ULK1 to regulate autophagy through PI3K/AKT/mTOR pathway.Stem cells translational medicine · 2024Article
- The non-invasive serum biomarkers contributes to indicate liver fibrosis staging and evaluate the progress of chronic hepatitis B.BMC infectious diseases · 2024Article
- Outcomes of endoscopic submucosal dissection in cirrhotic patients: First American cohort.World journal of hepatology · 2024Article
- Clinical Indicators of Bone Deterioration in Alcoholic Liver Cirrhosis and Chronic Alcohol Abuse: Looking beyond Bone Fracture Occurrence.Diagnostics (Basel, Switzerland) · 2024Article
- Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019.BMC public health · 2024Article
- Liver Cirrhosis of Unknown Etiology and Its Predictors in Eastern Ethiopia.Risk management and healthcare policy · 2024Article
- Global burden of adult non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been steadily increasing over the past decades and is expected to persist in the future.Translational gastroenterology and hepatology · 2024Article
- Pharmacological considerations in pharmacotherapy of rheumatology patients with liver disease: a brief narrative review.Reumatologia · 2024Review
- Trends of hospitalisation for patients with liver cirrhosis in Ningxia, China: a cross-sectional study.BMJ open · 2023Article
- From Phenomenon to Essence: A Newly Involved lncRNA Kcnq1ot1 Protective Mechanism of Bone Marrow Mesenchymal Stromal Cells in Liver Cirrhosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Liver Injury Associated with COVID-19 Infection: Pathogenesis, Histopathology, Prognosis, and Treatment.Journal of clinical medicine · 2023Review
- The sex life of male patients with cirrhosis and its organic factors: What we have got so far?PloS one · 2023Observational
- Global, regional, and national burden of 10 digestive diseases in 204 countries and territories from 1990 to 2019.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the pattern and prevalence trends of liver cirrhosis caused by specific etiologies.
resultsGlobally, the number of prevalent cases increased 74.53% from 1990 to 2017. The ASR increased 0.75 per year. The most pronounced increases were found in middle-high and high socio-demographic index (SDI) regions, especially in the Caribbean and Latin America. Among the etiologies, non-alcoholic steatohepatitis (NASH) related liver cirrhosis accounted for 59.46% of the cases. The ASR increased 1.74 per year, and the increase was observed in all 5 SDI regions. In addition, the ASR of liver cirrhosis caused by alcohol also increased in both sexes and all SDI regions. In contrast, the ASR of liver cirrhosis caused by hepatitis B virus (HBV) and hepatitis C virus (HCV) decreased, especially in middle and low-middle SDI regions.
conclusionsThough the number of people suffering from HBV and HCV decreases, liver cirrhosis is still a major threat to health. Additionally, the number of people with cirrhosis caused by alcohol and NASH continues to grow. Thus, more targeted and specific strategies should be established based on etiology and prevalence trends of liver cirrhosis.
methodsWe collected data based on Global Burden of Disease (GBD) 2017 study. The age standardized prevalence rate (ASR) and estimated annual percentage changes (EAPC) were used to estimate the trends in prevalence by population, etiologies and regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.